David T. Rubin, MD, FACG

University of Chicago Medicine Inflammatory Bowel Disease Center

Poster(s):

• B0364 - Matching-Adjusted Indirect Comparison of Upadacitinib versus Vedolizumab as Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis
  Monday, October 24, 2022

  10:00 AM – 12:00 PM ET

• B0365 - Impact of Mirikizumab Treatment on Health-Related Quality of Life in Patients With Crohn’s Disease: A Phase 2 Study Analysis Using the SF-36
  Monday, October 24, 2022

  10:00 AM – 12:00 PM ET

• B0366 - Effect of Mirikizumab on Bowel Urgency Clinically Meaningful Improvement and Remission: Results From the Phase 3 LUCENT Induction and Maintenance Studies
  Monday, October 24, 2022

  10:00 AM – 12:00 PM ET

• B0367 - Health-Related Quality of Life with Guselkumab Induction and Maintenance Therapy as Measured by PROMIS-29: Results Through Week 48 of Phase 2 GALAXI 1 Study
  Monday, October 24, 2022

  10:00 AM – 12:00 PM ET

• B0368 - Hepatic Safety of Ozanimod in Ulcerative Colitis and Relapsing Multiple Sclerosis Phase 3 Trials
  Monday, October 24, 2022

  10:00 AM – 12:00 PM ET

• B0369 - An Insight into the Patient’s Perspective of Ulcerative Colitis Flares via Analysis of Online Public Forum Posts: Key Triggers and Symptoms of Flares
  Monday, October 24, 2022

  10:00 AM – 12:00 PM ET

• B0370 - Presence of Risk Factors Associated With Colectomy Among Patients With Colectomy in the Tofacitinib OCTAVE Ulcerative Colitis Clinical Program
  Monday, October 24, 2022

  10:00 AM – 12:00 PM ET